If you are wondering whether GSK shares offer good value right now, you are not alone, especially with the stock firmly back on many investors' watchlists. The share price closed at £19.46, with ...

A clean fourth-quarter beat pushed GSK ahead of its own medium-term targets. Yet management chose to set a deliberately ...

Wave claimed GSK is handing back rights to the frontrunning program not because of questions about its potential, but because Wave is better suited to quickly advance a rare disease therapy.

New boss Luke Miels knows perils of overpromising but there is growing sense pharma firm is closer to filling potential ...

GSK plc reports fourth-quarter earnings Wednesday, marking the first results under new Chief Executive Luke Miels as the pharmaceutical giant navigates a critical juncture between looming patent ...

Some Delaware Supreme Court justices signaled they may be skeptical of a bid by GSK Plc, Pfizer Inc. and other drugmakers to overturn a judge who allowed more than 80,000 lawsuits to proceed to trial ...

GSK’s $2.2 billion agreement to acquire RAPT Therapeutics highlights a practical truth about immunology: some clinically ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...

Hello, everyone. Welcome to today's call and webcast. The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to Slide 2. This is the usual ...

GSK (GSK) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.59 per share a year ago. These figures are ...

Dec 12 (Reuters) - The European Medicines Agency has recommended the approval of GSK's (GSK.L), opens new tab add-on drug to treat asthma and a chronic inflammatory sinus condition, the company said ...